Literature DB >> 32684433

Robotic treatment of bowel endometriosis.

Christine Hur1, Tommaso Falcone2.   

Abstract

Endometriosis describes a condition with the presence of ectopic endometrial glands and stroma outside the endometrial cavity that affects up to 15% of reproductive-aged women. Of women affected with endometriosis, 3.8-37% will have endometriosis involving the bowel, primarily the rectosigmoid colon. While medical management is often recommended as a first-line therapy, it is not curative, and surgery is often required as an adjunct for the management of symptoms. Minimally invasive surgery has become the standard of care for managing these patients. The use of robotic-assisted laparoscopy offers benefits that may allow surgeons to perform these challenging surgical cases using a minimally invasive technique. For lesions that affect the colon, there are three primary techniques used for removal which include: 1) rectal shaving, 2) discoid excision and 3) segmental resection. The decision to pursue one approach over another is largely dependent on the number of lesions present, a lesion's size and depth of invasion as well as the involved circumference of the bowel. The available evidence of using robotic-assisted laparoscopy in cases of bowel endometriosis is limited in the literature. In this review, we will summarize the role of robotic-assisted laparoscopy in the management of bowel endometriosis.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bowel endometriosis; Colorectal endometriosis; Deep infiltrating endometriosis; Robotic-assisted laparoscopic surgery; Segmental bowel resection

Mesh:

Year:  2020        PMID: 32684433     DOI: 10.1016/j.bpobgyn.2020.05.012

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  1 in total

1.  miR-424-5p combined with miR-17-5p has high diagnostic efficacy for endometriosis.

Authors:  Chunli Lin; Saili Zeng; Miaojie Li
Journal:  Arch Gynecol Obstet       Date:  2022-04-03       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.